| Drug General Information |
| Drug ID |
D04RCT
|
| Former ID |
DCL000751
|
| Drug Name |
CHF-3381
|
| Drug Type |
Small molecular drug
|
| Indication |
Neuropathic pain [ICD9: 356.0, 356.8; ICD10:G64, G90.0]
|
Phase 2 |
[1],
[2]
|
|---|
| Therapeutic Class |
Analgesics
|
| Company |
Chiesi
|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C11H14N2O
|
| Canonical SMILES |
C1C(CC2=CC=CC=C21)NCC(=O)N
|
| InChI |
1S/C11H14N2O/c12-11(14)7-13-10-5-8-3-1-2-4-9(8)6-10/h1-4,10,13H,5-7H2,(H2,12,14)
|
| InChIKey |
MNLULKBKWKTZPE-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| PubChem Substance ID |
15188851, 22585836, 40282178, 75724008, 128621049, 134223472, 134339241, 135261923, 137004968, 143117008, 145860429, 198985653, 225073309, 226728209
|
| SuperDrug ATC ID |
L01XX16
|
| SuperDrug CAS ID |
cas=000459869
|
| Target and Pathway |
| Target(s) |
Amine oxidase [flavin-containing] B |
Target Info |
Inhibitor |
[2]
|
|---|
| NMDA receptor |
Target Info |
Antagonist |
[2]
|
| Amine oxidase [flavin-containing] A |
Target Info |
Inhibitor |
[2]
|
|
BioCyc Pathway
|
Superpathway of tryptophan utilization
|
|
Tryptophan degradation via tryptamine
|
|
Dopamine degradation
|
|
Putrescine degradation III
|
|
Noradrenaline and adrenaline degradationPWY66-401:Superpathway of tryptophan utilization
|
|
Noradrenaline and adrenaline degradation
|
|
Serotonin degradation
|
|
Superpathway of melatonin degradation
|
|
Melatonin degradation II
|
|
KEGG Pathway
|
Glycine, serine and threonine metabolism
|
|
Arginine and proline metabolism
|
|
Histidine metabolism
|
|
Tyrosine metabolism
|
|
Phenylalanine metabolism
|
|
Tryptophan metabolism
|
|
Drug metabolism - cytochrome P450
|
|
Metabolic pathways
|
|
Serotonergic synapse
|
|
Dopaminergic synapse
|
|
Cocaine addiction
|
|
Amphetamine addiction
|
|
Alcoholismhsa00260:Glycine, serine and threonine metabolism
|
|
Alcoholism
|
|
NetPath Pathway
|
IL4 Signaling Pathway
|
|
PANTHER Pathway
|
Adrenaline and noradrenaline biosynthesis
|
|
5-Hydroxytryptamine degredation
|
|
Dopamine receptor mediated signaling pathwayP00001:Adrenaline and noradrenaline biosynthesis
|
|
Dopamine receptor mediated signaling pathway
|
|
Pathway Interaction Database
|
Alpha-synuclein signaling
|
|
PathWhiz Pathway
|
Histidine Metabolism
|
|
Tyrosine Metabolism
|
|
Glycine and Serine Metabolism
|
|
Reactome
|
Norepinephrine Neurotransmitter Release Cycle
|
|
WikiPathways
|
Tryptophan metabolism
|
|
Dopamine metabolism
|
|
Phase 1 - Functionalization of compoundsWP706:SIDS Susceptibility Pathways
|
|
Biogenic Amine Synthesis
|
|
Oxidative Stress
|
|
Phase 1 - Functionalization of compounds
|
|
Neurotransmitter Release Cycle
|
|
Neurotransmitter Clearance In The Synaptic Cleft
|
|
Serotonin Transporter Activity
|
| References |
| REF 1 | Indantadol, a novel NMDA antagonist and nonselective MAO inhibitor for the potential treatment of neuropathic pain. IDrugs. 2007 Sep;10(9):636-44. |
|---|
| REF 2 | Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26. |
|---|
